Opinion|Videos|April 22, 2025
Comparing Biologic Treatment Patterns: Tildrakizumab vs Ustekinumab
Author(s)Aaron Farberg, MD
An expert discusses how comparative studies of FDA-approved psoriasis biologics are crucial for treatment optimization. This study compared tildrakizumab with ustekinumab, analyzing discontinuation, persistence, adherence, and switching. Results showed favorable persistence and adherence. Provider administration may have influenced outcomes, impacting clinical decisions.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Why is it so critical to have comparative studies with biologics FDA-approved for psoriasis?
- What were the objectives and methods of this study, and why is it important to analyze end points such as treatment discontinuation, persistence, adherence, and switching/reinitiation?
- What were the key results seen in terms of these key end points such as treatment discontinuation, persistence, adherence, and switching/reinitiation?
- Do you believe that having a health care provider–administered biologic impacted the results?
- Will the results from this study impact your clinical decision-making?
Advertisement
Related to this article
Rosacea is likely missed, not rare, in skin of color, as low suspicion and hard-to-see redness delay diagnosis, said Hilary Baldwin, MD.
Hidradenitis suppurativa diagnosis often takes 7 to 10 years, and patients with skin of color often present with tunnels and scarring already in place.
In HIV, lymphoma survival tracks tumor stage and CD4 count, not viral suppression, a Spanish cohort shows.
Polyphenols show lab promise for endometriosis, but human evidence is thin, and the best resveratrol pain trial was negative.
Those using e-cigarettes were more likely to develop cataracts, and those receiving cataract surgery less likely to develop depression and anxiety.
The conference session featured updates on several clinical trials, including the BRUNELLO trial, for treatment of diabetic macular edema (DME).
Experts explain why access to specialty cancer care, open dialogue, and patient education are essential to building trust and making informed treatment decisions.
An intraoperative indocyanine green (ICG) fluorescence imaging protocol in sarcoma surgery detected 14 of 15 positive margins vs 4 of 15 for surgeons, though its specificity was 41.7% vs 88.9%.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Once-Monthly Subcutaneous Olanzapine for Schizophrenia
2
A New Mechanism for DME in the BRUNELLO Trial: Donald J. D’Amico, MD
3
Using Complement Inhibitors in GA Comes With Pros and Cons
4
Pairing VYD2311 With mRNA COVID-19 Vaccines: Michael Mina, MD, PhD
5